El Hospital Universitari i Politècnic La Fe de Valencia has taken a step that changes the landscape of public healthcare in Spain. The recent authorization of the Spanish Agency for Medicines and Health Products (AEMPS) It allows the center to produce its own gene therapy drugs, including the CAR-T cell therapies, considered one of the great revolutions in the approach to certain hematological cancers.
With this accreditation, the La Fe Advanced Therapies Unit It ceases to depend on external suppliers for the manufacture of these treatments and becomes a production node within the public network. This strengthens the strategic autonomy of the Valencian healthcare system in a field as sensitive as precision medicine, where response times and proximity to production can make all the difference for many patients.
A change of role: from managing center to CAR-T manufacturer
So far, obtaining advanced therapies such as CAR-T It used to rely on external laboratories or facilities located far from the hospital itself, with logistical procedures that could lengthen the process. With the new authorization from the AEMPS, La Fe will be able to produce their gene and cell therapy drugs in-houseThis translates into more agile processes and a greater capacity to adapt to the needs of each patient.
This change of role will allow significantly reduce waiting times of people with serious oncohematological diseases, especially patients with leukemias and lymphomas that require rapid interventions. In these cases, every week counts, and having the manufacturing capacity in the hospital itself can become a key factor in accessing treatment at the right time.
During an institutional visit to the center, the General Director of Pharmacy, Elena GrasShe emphasized that this certification represents "a decisive step for the leadership of the Valencian public health system in precision medicine." She was accompanied by... Hospital manager, José Luis Poveda, as well as the Juan Eduardo MegÃas, head of the Regional Office of Predictive, Personalized and Advanced Therapies Medicinewho highlighted the value of the Valencian Community now having its own production center.
With this accreditation, La Fe becomes the first hospital in the Valencian Community equipped to manufacture gene therapy with the official endorsement of the AEMPS. This places the Valencian center in the league of major European hospitals that, in addition to treating patients, actively participate in the production and development of advanced therapies.
Beyond the immediate impact on healthcare, the measure reinforces La Fe's position as a leader in personalized medicine and innovative therapies within the public system, an area in which competition between territories to attract investment and scientific talent is increasingly fierce.
From antiviral T lymphocytes to the leap towards CAR-T
The new AEMPS certification did not come from scratch: La Fe already had previous experience in the production of cells for therapeutic useUntil now, the unit had authorization to manufacture Non-expanded IFNgamma+ allogeneic differentiated peripheral blood T lymphocytes after stimulation with viral peptide, a line of work linked to antiviral cell therapies.
In that context, the hospital participates as production center in the first trial with antiviral cell therapy developed entirely in Spain, in collaboration with the Vall d'Hebron Hospital Institute of Oncology (VHIO) and the Bank of Blood and Teixits of Barcelona (BST)This trajectory has served as a technical and organizational basis for making the leap into manufacturing more complex gene therapy drugs, such as CAR-T.
The current recognition substantially broadens the scope of the unit, shifting it from a framework focused on antiviral cell therapies to a scenario where it can to produce treatments targeting high-risk oncohematological pathologiesIn this way, the hospital integrates in one space the experience accumulated in clinical trials with immune cells and the new capacity to develop advanced therapy products with an antitumor focus.
The possibility of combining scientific capacity, certified infrastructure, and experience in clinical trials This places La Fe in a privileged position to promote new translational research projects. These are initiatives that directly connect laboratory advances with everyday clinical practice, something especially relevant in fields such as immunotherapy.
GYA01: the new CAR-T for high-risk leukemias
One of the first concrete results of this authorization will be the start of a Phase I/IIa clinical trial with the drug GYA01A CAR-T cell therapy designed to address particularly complex situations. This drug is intended for patients with relapsed or refractory acute myeloid leukemia (AML) and with T-cell acute lymphoblastic leukemia (T-ALL) in cases that are very difficult to manage with the usual treatments.
The most relevant characteristic of GYA01 is their approach as a bridge therapy before hematopoietic transplantationIts main objective is to achieve a the most complete possible elimination of tumor cells before proceeding with the transplant, with the intention of minimizing the probability of subsequent relapses, one of the major challenges in this type of disease.
For many patients with refractory AML or T-cell ALL, the available therapeutic options are limited and, at times, insufficiently effective. The launch of this trial at La Fe Hospital opens the door for a profile of patients with particularly unfavorable prognosis can access treatment strategies that, until recently, were seen as something very distant within the public health system.
The Phase I/IIa study design will allow to evaluate both the safety and evidence of efficacy of GYA01 in a small number of patients, with the possibility of expanding the sample if the initial results are favorable. These types of trials are essential for consolidating the clinical evidence that then serves as the basis for regulatory and funding decisions.
In addition to its potential individual impact on the patients included, the accumulated experience with GYA01 at La Fe can contribute to generate useful knowledge for other European teams working on CAR-T, facilitating synergies and future collaborations in the field of advanced therapies against leukemia.
Quality guarantees: Good Manufacturing Practices and European standard
The AEMPS authorization comes after verifying that La Fe's facilities, staff and procedures comply with the Good Manufacturing Practices (GMP)This requirement is key in the field of advanced therapies, where any deviation in the process can directly affect the safety and efficacy of the treatment.
Having the GMP seal means that The production of cell and gene therapies at La Fe is carried out with levels of rigor comparable to those of the European pharmaceutical industry.From cleanrooms to the traceability of each sample, the entire circuit must undergo constant controls, audits, and very strict protocols.
This certification places the Valencian hospital at the same level as other leading centers such as the Hospital ClÃnic of BarcelonaLa Fe, considered a pioneer in Europe and with one of the most established track records in Spain in CAR-T therapies, thus joins a select group of public hospitals capable of to produce and administer these treatments with full regulatory guarantees.
The official validation by the AEMPS not only endorses the infrastructure, but also the qualification of the multidisciplinary team Those involved include specialists in hematology, hospital pharmacy, immunology, molecular biology, specialized nursing, and laboratory technicians, among other profiles. All of them are essential to ensure that each manufactured dose meets the required standards.
In a context where advanced therapies are progressively spreading across Europe, having centers like La Fe, with in-house manufacturing capacity and strict compliance with GMPThis contributes to strengthening Spain's position on the international map of biomedicine and attracting new research projects funded at the community level.
Impact on patients: shorter wait times and greater responsiveness
One of the most tangible effects of this new stage will be the reduction of access times to CAR-T therapiesBy not depending on the logistics and schedules of external laboratories, the hospital will be able to organize the extraction, processing, and reinfusion of each patient's cells more flexibly, something especially relevant in rapidly evolving diseases.
For those who suffer high-risk leukemias or lymphomasEvery day counts. Having our own production capacity allows for a shorter journey between diagnosis, treatment indication, and effective administration, which in practice can translate into... greater chances of response and control of the disease.
Furthermore, the fact that manufacturing takes place within a leading public hospital facilitates a very close coordination between the clinical teams and the advanced therapies production areaThis proximity facilitates rapid adjustments to protocols, more personalized monitoring, and more consistent long-term follow-up.
For patients and their families, not having to travel to other regions or depend on distant centers also represents a relief in logistical and emotional terms. The possibility of receiving cutting-edge treatments in their own healthcare environment It reduces the burden associated with long journeys, stays away from home, and added paperwork at already complex times.
In parallel, the experience that accumulates at La Fe will contribute to Refine patient selection criteria, optimize care pathways, and improve outcome assessmentThis could benefit the entire healthcare system in the medium term by providing real data on the impact of these therapies in daily clinical practice.
Strategic dimension: CERTERA and the drive for biomedical innovation
Beyond the healthcare aspect, the authorization to manufacture CAR-T therapies has a clearly strategic interpretation. La Fe is the only Valencian center integrated into the State Network Consortium for the Development of Advanced Therapy Medicines (CERTERA), a structure that seeks to coordinate and enhance public resources in this area throughout the country.
The Department of Health of the Valencian Community This recognition is seen as further evidence to support the claim for a more prominent role on the national biomedical innovation map. In fact, the regional government has appealed the decision to locate CERTERA's headquarters in Madrid and Barcelona, ​​arguing that the Valencian bid is "solid and sound" in scientific and technological terms.
In this context, the certification of La Fe as gene therapy drug manufacturing center This reinforces the idea that the region is in a position to assume structural responsibilities within the consortium. It's not just about providing care, but about contributing industrial infrastructure, critical mass of researchers and regulatory experience in a rapidly expanding sector.
As Elena Gras pointed out, this recognition helps to consolidate the image of the Valencian Community as strategic location for the development of next-generation personalized medicineIn a scenario where different autonomous communities and European regions compete to attract projects, funds and talent, having a public hospital certified in CAR-T is an important asset.
At the same time, La Fe's active participation in CERTERA can help synergies with other national and international nodesFacilitating multicenter trials and accelerating the translation of basic research into clinical practice. All of this contributes to advanced therapies ceasing to be exceptional and becoming progressively integrated into the standard portfolio of public healthcare services.
With the authorization from the AEMPS to manufacture CAR-T therapies and other gene therapy drugs, La Fe Hospital consolidates a model in which assistance, production, and research go hand in hand within the public system.The combination of less external dependence, compliance with European standards, the implementation of trials such as GYA01, and participation in state networks such as CERTERA paints a picture in which Valencian patients, and by extension those throughout the country, will be able to access increasingly personalized treatments without leaving the public health system, which reinforces both the equity and the capacity for innovation of the system.